Compare MAX & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAX | TECX |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.7M | 618.9M |
| IPO Year | 2020 | 2018 |
| Metric | MAX | TECX |
|---|---|---|
| Price | $12.44 | $21.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $14.50 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 905.3K | 222.1K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.81 | ★ 40.70 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $18.87 | N/A |
| Revenue Next Year | $8.14 | N/A |
| P/E Ratio | $13.38 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $15.60 |
| 52 Week High | $14.70 | $39.53 |
| Indicator | MAX | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 66.01 | 33.35 |
| Support Level | $11.73 | $20.52 |
| Resistance Level | $14.42 | $23.61 |
| Average True Range (ATR) | 0.57 | 1.13 |
| MACD | 0.31 | 0.23 |
| Stochastic Oscillator | 99.32 | 18.59 |
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.